2016 Fiscal Year Final Research Report
Development of hippocampal neurogenesis-promoting drugs as a target for the treatment and prevention of psychiatric disorders
| Project/Area Number |
26460102
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Pharmacology in pharmacy
|
|---|
| Research Institution | Tohoku Medical and Pharmaceutical University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
TAN-NO Koichi 東北医科薬科大学, 薬学部, 教授 (20207260)
OBARA Yutarou 山形大学, 医学部, 准教授 (40400270)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Keywords | 神経新生 / 認知症 / うつ病 / 脳由来神経栄養因子 / 動物モデル |
|---|
| Outline of Final Research Achievements |
The aim of this study was to explore the effects and underlying mechanisms of a newly synthesized scabronine G - methylester (SG-ME) on memory impairment in olfactory bulbectomized (OBX) mice, experimental animal models of depression and dementia. We observed that the memory impairment in OBX mice was improved at 24 hours after an intracerebroventricular (i.c.v.) injection of SG-ME. The present study has shown that SG-ME has anti-dementia effect, and the SG-ME activity to improve impaired memory is accompanied by enhancement of hippocampal cell proliferation mediated via activation of brain-derived neurotrophic factor - extracellular signal-regulated kinase - cAMP-response element binding protein (BDNF-ERK-CREB) signal pathway on neuronal cells. These results indicate that SG-ME may become a potential leading compound for drug development for Alzheimer's disease.
|
| Free Research Field |
中枢薬理学
|
